No abstract

No abstract

disposition of ziprasidone was characterized in patients for this study. The results were consistent with predictions from the single dose, showing attainment of peak exposure within approximately 30 min, dose-related increases in exposure, and little drug accumulation. The model refinement afforded from the multiple-dose patient data was then used for population modeling and covariate identification for phase III studies of 1M ziprasidone. Thus, the approach used here demonstrated that population pharmacokinetic modeling is a useful tool in understanding drug disposition in subject populations where pharmacokinetic sampling is limited. Ziprasidone lM has a linear phannacokinetic profile. Therapeutic plasma concentrations are attained rapidly.